- Previous Close
0.0001 - Open
0.0001 - Bid --
- Ask --
- Day's Range
0.0001 - 0.0001 - 52 Week Range
0.0001 - 0.0100 - Volume
827 - Avg. Volume
56 - Market Cap (intraday)
3,213 - Beta (5Y Monthly) -29.32
- PE Ratio (TTM)
0.00 - EPS (TTM)
0.0200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Rebus Holdings, Inc., together with its subsidiaries, focuses on the research and development of precision therapeutics for the treatment of cancer. Its lead asset is RT-AR001, an adenosine receptor antagonist for tumor infiltration and enhanced outcomes when administered intra-tumorally. Rebus Holdings, Inc. was incorporated in 2003 and is based in Westlake Village, California.
www.rebus-corp.comRecent News: RBSH
View MorePerformance Overview: RBSH
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RBSH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RBSH
View MoreValuation Measures
Market Cap
3.21k
Enterprise Value
308.21k
Trailing P/E
0.01
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.52
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-215.79%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
570k
Diluted EPS (ttm)
0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
5k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.16M